FORM 10-QSB

                       SECURITIES AND EXCHANGE COMMISSION
                             WASHINGTON, D.C. 20549

(Mark One)

[X]  QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE
ACT OF 1934

     For the Quarterly period ended December 31, 2000

OR

[ ]  TRANSITION REPORT PURUSANT TO SECTION 13 OR 15(d) OF THE SECURITIES
EXCHANGE ACT OF 1934

Commission file number 0-14306

                     INTERCELL CORPORATION
                     ---------------------
(Exact name of small business issuer as specified in its charter)

          Colorado                                  84-0928627
          --------                                  ----------
(State or other jurisdiction of                  (I.R.S. employer
 incorporation or organization)                identification number)

          370 17th Street, Suite 3580
            Denver, Colorado 80202
(Address of principal executive offices) (Zip Code)

Issuer's telephone number, including area code:  (303) 592-1010

                       Not applicable
(Former name, former address or former fiscal year,
         if changed since last report)

Indicate by check mark whether the issuer (1) has filed all reports required to
be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during
the preceding 12 months (or for such shorter period that the registrant was
required to file such reports), and (2) has been subject to such filing
requirements for the past 90 days.   Yes   X   No
                                          ---      ---

As of January 31, 2001 there were 99,898,188 shares of the registrant's sole
class of common shares outstanding.

Transitional Small Business Disclosure Format          Yes        No   X
                                                            ----     -----

<PAGE>



                     INTERCELL CORPORATION AND SUBSIDIARIES
                                      INDEX


PART I - FINANCIAL INFORMATION


ITEM 1.  FINANCIAL STATEMENTS                                            PAGE
                                                                         ----


    Independent Accountants' Report                                        1

    Condensed Consolidated Balance Sheet
       December 31, 2000                                                   2

    Condensed Consolidated Statements of Operations
       Three Months Ended December 31, 2000 and 1999 (As restated)         3

    Condensed Consolidated Statement of Changes in Stockholders' Deficit
       Three Months Ended December 31, 2000                                5

    Condensed Consolidated Statements of Cash Flows
       Three Months Ended December 31, 2000 and 1999 (As restated)         6

    Notes to Condensed Consolidated Financial Statements
       Three Months Ended December 31, 2000 and 1999                       7


ITEM 2.  MANAGEMENT'S DISCUSSION AND ANALYSIS                             13


PART II - OTHER INFORMATION                                               16


ITEM 2.  CHANGES IN SECURITIES                                            16

ITEM 6.  EXHIBITS AND REPORTS IN FORM 8-K                                 16


    SIGNATURES                                                            17





















<PAGE>






                         INDEPENDENT ACCOUNTANTS' REPORT
                         -------------------------------



Board of Directors
Intercell Corporation

We have reviewed the accompanying condensed consolidated balance sheet of
Intercell Corporation and subsidiaries as of December 31, 2000, and the related
condensed consolidated statements of operations, changes in stockholders'
deficit and cash flows for the three-month period then ended. These condensed
consolidated financial statements are the responsibility of the Company's
management.

We conducted our review in accordance with standards established by the American
Institute of Certified Public Accountants. A review of interim financial
information consists principally of applying analytical procedures to financial
data and making inquiries of persons responsible for financial and accounting
matters. It is substantially less in scope than an audit conducted in accordance
with generally accepted auditing standards, the objective of which is the
expression of an opinion regarding the financial statements taken as a whole.
Accordingly, we do not express such an opinion.

Based on our review, we are not aware of any material modifications that should
be made to the accompanying condensed consolidated financial statements for them
to be in conformity with generally accepted accounting principles.


GELFOND HOCHSTADT PANGBURN, P.C.


Denver, Colorado
February 12, 2001
























                                        1

<PAGE>




                     INTERCELL CORPORATION AND SUBSIDIARIES
                      CONDENSED CONSOLIDATED BALANCE SHEET
                                   (UNAUDITED)
                                DECEMBER 31, 2000
<TABLE>
<CAPTION>

Assets
------
<S>                                                            <C>
Current assets:
  Cash and cash equivalents                                    $     69,000
                                                                 ----------
    Total current assets                                             69,000
Investment in land held for sale                                    247,000
Restricted cash                                                      22,000
                                                                 ----------
       Total assets                                            $    338,000
                                                                 ==========

Liabilities and Stockholders' Deficit
-------------------------------------
Current liabilities:
  Accounts payable                                             $    123,000
  Accrued liabilities                                               264,000
  Notes payable - related parties                                    23,000
  Notes payable - other                                              50,000
  Deferred gain under agreement to sell affiliate stock             723,000
  Liabilities of discontinued operations                          1,086,000
                                                                 ----------
    Total liabilities (all current)                               2,269,000
                                                                 ----------

Commitment and Contingencies

Stockholders' deficit:
  Convertible preferred stock; 10,000,000 shares authorized:
    Series C; 26 shares issued and outstanding
     (liquidation preference of $344,000)                           288,000
    Series D; 1,080 shares issued and outstanding
     (liquidation preference of $3,186,000)                       2,853,000
    Series E; 1,000 shares issued and outstanding
     (liquidation preference of $105,000)                             4,000
  Warrants to acquire common stock                                3,045,000
  Common stock; no par value; 100,000,000 shares authorized
    99,898,188 shares issued and outstanding                     22,762,000
  Additional paid-in capital                                      7,242,000
  Accumulated deficit                                           (37,431,000)
  Receivable under agreement to sell affiliate stock            (   694,000)
                                                                 ----------
      Total stockholders' deficit                               ( 1,931,000)
                                                                 ----------
        Total liabilities and stockholders' deficit            $    338,000
                                                                 ==========
<FN>

See accompanying notes to condensed consolidated financial statements.

</TABLE>

                                        2

<PAGE>




                     INTERCELL CORPORATION AND SUBSIDIARIES
                 CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
                                   (UNAUDITED)

<TABLE>
<CAPTION>

                                                         Three Months Ended
                                                            December 31,
                                                         ------------------
                                                         2000          1999
                                                         ----          ----
                                                                  (As restated,
                                                                     Note 1)
<S>                                                   <C>            <C>

General and administrative expense                    $  42,000        85,000
Impairment of investment in land (Note 2)                53,000           -
                                                        -------       -------

Loss from operations                                   ( 95,000)     ( 85,000)
                                                        -------       -------

Gain on sale and exchange of affiliate
  stock (Notes 6 and 7)                                  74,000           -
Interest income                                           1,000         1,000
Interest expense                                       (  3,000)     ( 22,000)
                                                        -------       -------
                                                         72,000      ( 21,000)
                                                        -------       -------

Loss from continuing operations                        ( 23,000)     (106,000)
                                                        -------       -------

Discontinued operations:
  Gain on disposal of subsidiaries (Notes 6 and 7)       56,000           -
                                                        -------       -------

Gain from discontinued operations                        56,000           -
                                                        -------       -------

Net income (loss)                                        33,000      (106,000)

Deemed dividend on Series C and D preferred stock
  relating to in-the-money conversion terms            ( 14,000)     (  7,000)
Accrued dividends on Series D and E preferred stock    ( 39,000)     ( 38,000)
Accretion on Series C and E preferred stock            (  5,000)     ( 14,000)
                                                        -------       -------

Net loss applicable to common stockholders            $( 25,000)     (165,000)
                                                        =======       =======

                                  (Continued)

</TABLE>





                                        3

<PAGE>




                     INTERCELL CORPORATION AND SUBSIDIARIES
                 CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
                                   (UNAUDITED)
                                   (CONTINUED)

<TABLE>
<CAPTION>

                                                         Three Months Ended
                                                            December 31,
                                                         ------------------
                                                         2000          1999
                                                         ----          ----
                                                                  (As restated,
                                                                     Note 1)
<S>                                                   <C>            <C>

Net loss per share, applicable
  to common stockholders:
   Basic:
    Loss from continuing operations                   $(   0.00)     (   0.00)
    Gain from discontinued operations                      0.00          0.00
                                                        -------       -------

  Net loss                                            $(   0.00)     (   0.00)
                                                        =======       =======

   Diluted:
    Loss from continuing operations                   $(   0.00)     (   0.00)
    Gain from discontinued operations                      0.00          0.00
                                                        -------       -------

  Net loss                                            $(   0.00)     (   0.00)
                                                        =======       =======

Weighted average number of common
  shares outstanding
   Basic                                             99,898,188    80,949,160
                                                     ==========    ==========
   Diluted                                           99,898,188    80,949,160
                                                     ==========    ==========

<FN>

See accompanying notes to condensed consolidated financial statements.

</TABLE>













                                        4

<PAGE>




                     INTERCELL CORPORATION AND SUBSIDIARIES
      CONDENSED CONSOLIDATED STATEMENT OF CHANGES IN STOCKHOLDERS' DEFICIT
                                   (UNAUDITED)
                      THREE MONTHS ENDED DECEMBER 31, 2000

<TABLE>
<CAPTION>

                         Convertible
                       Preferred Stock        Warrants to           Common Stock
                       ---------------          acquire             ------------
                      Shares      Amount      common stock      Shares        Amount
                      ------      ------      ------------      ------        ------
<S>                   <C>       <C>            <C>            <C>           <C>
Balances,
  October 1, 2000     2,106     $3,087,000     3,045,000      99,898,188    $22,762,000

Amortization of
  deemed dividend       -           14,000           -               -              -
Accrual of
  preferred stock
  dividend              -           39,000           -               -              -
Accretion on
  preferred stock       -            5,000           -               -              -
Net income
                      -----      ---------     ---------      ----------     ----------
Balances,
  December 31, 2000   2,106     $3,145,000     3,045,000      99,898,188    $22,762,000
                      =====      =========     =========      ==========     ==========


                                          Receivable
                                            under
                                          agreement
                           Additional      to sell                          Total
                             paid-in      affiliate     Accumulated     stockholders'
                             capital        Stock         deficit          deficit
                             -------        -----         -------          -------
<S>                         <C>           <C>           <C>              <C>
Balances,
  October 1, 2000           7,242,000     (694,000)     (37,406,000)     (1,964,000)

Amortization of
  deemed dividend                 -            -        (    14,000)            -
Accrual of
  preferred stock
  dividend                        -            -        (    39,000)            -
Accretion on
  preferred stock                 -            -        (     5,000)            -
Net income                                                   33,000          33,000
                            ---------      -------       ----------       ---------
Balances,
  December 31, 2000         7,242,000     (694,000)     (37,431,000)     (1,931,000)
                            =========      =======       ==========       =========

<FN>

See accompanying notes to condensed consolidated financial statements.

</TABLE>
                                        5

<PAGE>



                     INTERCELL CORPORATION AND SUBSIDIARIES
                 CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
                                   (UNAUDITED)
<TABLE>
<CAPTION>
                                                              THREE MONTHS ENDED
                                                                 DECEMBER 31,
                                                             --------------------
                                                             2000            1999
                                                             ----            ----
                                                                         (As restated,
                                                                            Note 1)
<S>                                                     <C>             <C>
Cash flows from operating activities:
 Net income (loss)                                      $    33,000     (   106,000)
 Less gain from discontinued operations                  (   56,000)            -
                                                          ---------      ----------
   Loss from continuing operations                       (   23,000)    (   106,000)
 Adjustments to reconcile loss from continuing
   operations to net cash used in operating
   activities of continuing operations:
  Loss from asset impairment                                 53,000             -
  Gain on sale and exchange of affiliate stock           (   74,000)            -
  Changes in operating assets and liabilities:
   Increase in accounts payable and accrued liabilities      18,000          90,000
                                                          ---------      ----------
    Net cash used in operating activities
     of continuing operations                            (   26,000)    (    16,000)
                                                          ---------      ----------

Cash flows from investing activities:
 Other assets                                                   -             7,000
                                                          ---------      ----------
    Net cash provided by investing activities
      of continuing operations                                  -             7,000
                                                          ---------      ----------

Cash flows from discontinued operations:
 Net cash used in operations                             (    5,000)            -
                                                          ---------      ----------

Net decrease in cash and cash equivalents                (   31,000)    (     9,000)
Cash and cash equivalents, beginning of period              100,000          10,000
                                                          ---------      ----------
Cash and cash equivalents, end of period                $    69,000           1,000
                                                          =========      ==========

Supplemental disclosure of noncash investing
 and financing activities:
                                                             2000            1999
                                                             ----            ----
Conversion of note payable due related
 party to common stock                                  $       -            95,000
Amortization of deemed dividend on preferred stock           14,000           7,000
Accrual of preferred stock dividend                          39,000          38,000
Accretion on preferred stock                                  5,000          14,000

<FN>

See accompanying notes to condensed consolidated financial statements.

</TABLE>
                                        6

<PAGE>



                     INTERCELL CORPORATION AND SUBSIDIARIES
              NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
                                   (UNAUDITED)
                  THREE MONTHS ENDED DECEMBER 31, 2000 AND 1999


1.  BUSINESS, ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES:
--------------------------------------------------------------------------


Presentation of Interim Information

The accompanying consolidated financial statements include the accounts of
Intercell Corporation, a Colorado corporation (the Company), and its
subsidiaries Sigma 7 Corporation (Sigma 7) and BMI Acquisition Group, Inc.
(BMI), (corporations that filed for voluntary liquidation under Chapter 7 of the
U.S. Bankruptcy Code on December 31, 1998), Particle Interconnect Corp., and
Arizcan Properties, Ltd.  All significant intercompany accounts and transactions
have been eliminated in consolidation.

Additionally as described below, the consolidated financial statements reflect
Nanopierce Technologies, Inc. (Nanopierce) as an investment accounted for under
the equity method of accounting through September 2000.  The Company's
investment in Nanopierce is carried at zero in the Company's financial
statements and therefore the equity method has been suspended and the Company's
share of Nanopierce's losses has not been recorded.  During the three months
ended December 31, 2000 the Company's voting ownership interest decreased below
20% (approximately 18% at December 31, 2000).

In the opinion of the management of the Company, the accompanying unaudited
consolidated financial statements include all material adjustments, including
all normal and recurring adjustments, considered necessary to present fairly the
financial position and operating results of the Company for the periods
presented.  The financial statements and notes are presented as permitted by
Form 10-QSB, and do not contain certain information included in the Company's
last Annual Report on Form 10-KSB for the fiscal year ended September 30, 2000.
It is the Company's opinion that when the interim statements are read in
conjunction with the September 30, 2000 Annual Report on Form 10-KSB, the
disclosures are adequate to make the information presented not misleading.
Interim results are not necessarily indicative of results for a full year or any
future period.



















                                        7

<PAGE>




                     INTERCELL CORPORATION AND SUBSIDIARIES
              NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
                                   (UNAUDITED)
                  THREE MONTHS ENDED DECEMBER 31, 2000 AND 1999


The Company incurred significant operating losses in 1999 and prior years and
has a working capital deficiency and a stockholders' deficit at December 31,
2000.  The Company has been able to sell and/or exchange shares of Nanopierce
common stock held by the Company for cash or in exchange for services or
liabilities in the past, and may be able to perform similar transactions during
2001, subject to various restrictions on such sales/exchanges of Nanopierce
common stock.  During the three months ended December 31, 2000 the Company
issued 37,000 shares of its stock of Nanopierce to settle certain litigation
(Note 7).  The Company has also been in discussions with investment bankers and
financial institutions attempting to raise funds to support current and future
operations.  This includes attempting to raise additional working capital
through the sale of additional capital stock (Note 3) or through the issuance of
debt.

Accounting for investment in Nanopierce and restatement of 1999 consolidated
financial statements

During the quarter ended September 30, 1999, the Company's ownership interest in
Nanopierce was reduced to below 50%.  In the previously issued September 30,
1999 consolidated financial statements, the Company reported Nanopierce as a
consolidated subsidiary through September 30, 1999, based on several factors
which were believed to constitute a controlling financial interest in Nanopierce
by Intercell, including common ownership by the President of the Company.

Subsequent to the original issuance of the Company's September 30, 1999,
consolidated financial statements, and based upon a further evaluation of the
factors utilized in determining a controlling financial interest, management
determined that beginning in July 1999, the Company's investment in Nanopierce
should be accounted for under the equity method of accounting.

At June 30, 1999, and through September 30, 1999, the Company's investment in
Nanopierce was $0.  Therefore, as a result of the Company's change to the equity
method to account for its investment in Nanopierce, the Company suspended
recognition of its proportionate share of Nanopierce's net loss beginning with
the fourth quarter ended September 30, 1999, and accordingly, the Company
restated its 1999 consolidated financial statements to reflect this accounting
change, as presented in the Company's September 30, 2000 Form 10-KSB.

















                                        8

<PAGE>




                     INTERCELL CORPORATION AND SUBSIDIARIES
              NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
                                   (UNAUDITED)
                  THREE MONTHS ENDED DECEMBER 31, 1999 AND 1998


In the previously issued December 31, 1999 consolidated financial statements,
included in the Company's December 31, 1999 Form 10-QSB, the Company had
previously reported Nanopierce as a consolidated subsidiary through December 31,
1999.  At September 30, 1999 and through December 31, 1999 the Company's
investment in Nanopierce continued to be $0, and the Company continued to
suspend recognition of its proportionate share of Nanopierce's net losses during
the quarter ended December 31, 1999.  Accordingly, the Company's consolidated
financial statements as of and for the quarter ended December 31, 1999 have been
restated to reflect the accounting change as follows:

                                     As previously
                                        Reported              As restated
                                        --------              -----------

     Total assets                    $   692,000             $   522,000
     Total liabilities                 6,280,000               5,675,000
     Stockholders' deficit            (5,588,000)             (5,153,000)

     Net loss                         (  904,000)             (  106,000)
     Net loss applicable to
      Common stockholders             (  963,000)             (  165,000)
     Net loss per share applicable
      to common stockholders:         (     0.01)             (     0.00)

On February 13, 2001, the Company filed an amended 10-QSB/A for the quarter
ended December 31, 1999 to report the restatement.

The summarized financial position and results of operations of Nanopierce as of
and for the periods ended December 31, 2000, was as follows:

Current assets                              $ 5,808,000
Long-term assets:
  Intellectual property         716,000
  Other                         381,000       1,097,000
                              ---------       ---------
Total assets                                $ 6,905,000
                                              =========

Current liabilities:
  Accounts payable and
   accrued expenses                              70,000
Stockholders' equity                          6,835,000
                                              ---------
Total liabilities and stockholders' equity  $ 6,905,000
                                              =========

                                    Three months ended
                                       December 31,
                                    ---------------
                                    2000          1999
                                    ----          ----
Revenues                       $    79,000   $       -
Net loss                       $(1,134,000)  $(  841,000)

                                        9

<PAGE>




                     INTERCELL CORPORATION AND SUBSIDIARIES
              NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
                  THREE MONTHS ENDED DECEMBER 31, 2000 AND 1999
                                   (UNAUDITED)


At September 30, 2000, the Company's ownership interest in Nanopierce's
outstanding common stock was approximately 25.3%.  In October 2000, Nanopierce
issued 118,207 shares of its common stock in connection with the conversion of
$150,000 of debt and accrued interest of $5,104 to equity, resulting in a .08%
decrease in the Company's ownership interest.  In October 2000, Nanopierce also
issued 9,532,520 shares of its common stock upon the exercise of a warrant,
resulting in a 4.2% decrease in the Company's ownership interest, and issued
4,531,613 shares of its common stock in exchange for cash of $7,500,000 ($1.655
per share) resulting in a 2.8% decrease in the Company's ownership interest.

At December 31, 2000, the Company owned 9,133,050 shares of Nanopierce common
stock (an approximate 18% ownership interest) with a market value of
approximately $7,400,000, based upon the closing bid price of $0.81 per share.
The Company is subject to various restrictions on the sale and/or exchange of
Nanopierce shares owned by the Company, which limits the marketability of this
investment.

Nanopierce is engaged in the design, development and licensing of products using
its intellectual property, the PI Technology.  The PI Technology consists of
patents, pending patent applications, patent applications in preparation, trade
secrets, trade names, and trade marks.  The PI Technology improves electrical,
thermal and mechanical characteristics of electronic products.  Nanopierce has
designated and is commercializing its PI Technology as the Nanopierce Connection
System (NCS) and markets the PI Technology to companies in various industries
for a wide range of applications.  Nanopierce has not realized any significant
revenue through December 31, 2000.


2.  INVESTMENT IN LAND HELD FOR SALE
------------------------------------

The investment in land held for sale consists of approximately 94 acres of
undeveloped rangeland located in Arizona.  The Company entered into a letter
agreement with a potential buyer that expires on March 31, 2001, and which
agrees to a sales price of $250,000, cash of $100,000 and a note for $150,000
due upon development of the property.  The Company concluded that an impairment
charge of $53,000 was necessary at December 31, 2000 to reduce the carrying
value of the land to its newly estimated fair value ($250,000) less estimated
costs to sell of $3,000.















                                        10

<PAGE>




                     INTERCELL CORPORATION AND SUBSIDIARIES
              NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
                  THREE MONTHS ENDED DECEMBER 31, 2000 AND 1999
                                   (UNAUDITED)


3.  AUTHORIZED CAPITAL
----------------------

The Company's authorized capital consists of, among other classes of securities,
100,000,000 common shares.  As of December 31, 2000 there are 99,898,188 common
shares issued and outstanding.  In addition, the Company has outstanding certain
classes of securities which are convertible into common shares which would, if
converted, cause the Company to exceed its authorized common shares.  This is
prohibited by the laws of the State of Colorado and therefore until the Company
is able to convene a Special Meeting of the Shareholders pursuant to the proxy
solicitation requirements of Section 14 of the Securities Act of 1934, and the
law of the State of Colorado, it cannot permit such conversions, which means the
Company is or will be in default of certain terms and conditions of such
instruments.  The securities affected consist of the following as of December
31, 2000:

         (1)  26 shares of Series C Preferred shares,
         (2)  1,080 shares of Series D Preferred shares,
         (3)  Warrants convertible into 2,227,450 shares; and
         (4)  Options convertible into 6,927,000 common shares.

The Company intends to promptly prepare and file proxy solicitation materials to
convene a Special Meeting of Shareholders to among other things, increase its
authorized common shares in an amount sufficient to permit the conversion of its
authorized and/or outstanding convertible securities.


4.  INCOME (LOSS) PER SHARE
---------------------------

SFAS No. 128, Earnings per Share, requires dual presentation of basic and
diluted earnings or loss per share (EPS) with a reconciliation of the numerator
and denominator of the basic EPS computation to the numerator and denominator of
the diluted EPS computation.  Basic EPS excludes dilution.  Diluted EPS reflects
the potential dilution that could occur if securities or other contracts to
issue common stock were exercised or converted into common stock or resulted in
the issuance of common stock that then shared in the earnings of the entity.

Basic income (loss) per share of common stock is computed based on the weighted
average number of common shares outstanding during the period.  Diluted EPS
includes the potential conversion of stock options, warrants, convertible debt
and convertible preferred stock.  Stock options, warrants, convertible debt and
convertible preferred stock are not considered in diluted EPS for those periods
with net losses in the calculation, as the impact of the potential common shares
(approximately 61,845,914 shares at December 31, 2000 and 68,556,050 at December
31, 1999) would be to decrease loss per share.








                                       11

<PAGE>




                     INTERCELL CORPORATION AND SUBSIDIARIES
              NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
                  THREE MONTHS ENDED DECEMBER 31, 2000 AND 1999
                                   (UNAUDITED)


5.  BUSINESS RISK
-----------------

The Company and its investment, Nanopierce, are subject to risks and
uncertainties common to technology-based companies, including rapid
technological change, dependence on principal products and third-party
technology, new product introductions and other activities of competitors,
dependence on key personnel, and limited operating history.


6.  DISCONTINUED OPERATIONS
---------------------------

Liabilities of discontinued operations at December 31, 2000, consist of
remaining BMI liabilities as follows:

Accounts payable and accrued liabilities                $   737,000
Notes payable                                               240,000
Other liabilities                                           109,000
                                                         ----------
                                                        $ 1,086,000
                                                         ==========

During the three months ended December 31, 2000, $135,000 of BMI liabilities
were satisfied in connection with the settlement of certain litigation against
the Company (see Note 7).  The liabilities of $1,086,000 remain on the books of
BMI as of December 31, 2000, pending a final judgment from the U.S. Bankruptcy
Court as to the disposition of these BMI liabilities.


7.  LITIGATION
--------------

During November, 2000, the Company agreed to settle certain litigation and
$135,000 of BMI liabilities by paying $5,000 in cash and exchanging 37,000
restricted common shares of Nanopierce common stock held by the Company (with a
carrying value of $0, a market value of $2.00 per share, and a aggregate market
value of $74,000).  Exchange of the shares resulted in a gain on exchange of
affiliate stock of $74,000 as well as a .07% decrease in the Company's ownership
interest in Nanopierce.  The Company recognized a $56,000 gain on the
settlement, which is presented as a gain on disposal of subsidiary.  The
settlement agreement further stipulates that should the value of the Nanopierce
shares be less than $100,000, based on the closing asked share price, one year
from the date of the settlement, the Company is to exchange additional shares
of Nanopierce in an amount sufficient to obtain the $100,000 value.

The Company is involved in various claims and legal actions arising in the
ordinary course of business.  In the opinion of management, the ultimate
disposition of these matters will not have a material adverse effect on the
financial statements of the Company.




                                       12

<PAGE>




ITEM 2.  MANAGEMENTS'S DISCUSSION AND ANALYSIS


GENERAL

     The statements contained in this Form 10-QSB, if not historical, are
forward-looking statements within the meaning of the Private Securities
Litigation Reform Act of 1995, and involve risks and uncertainties that could
cause actual results to differ materially from the results, financial or
otherwise, or other expectations described in such forward-looking statements.
Any forward-looking statement or statements speak only as of the date on which
such statements were made, and the Company undertakes no obligation to update
any forward-looking statement to reflect events or circumstances after the date
on which such statements are made or reflect the occurrence of unanticipated
events.  Therefore, forward-looking statements should not be relied upon as
prediction of actual future results.

PLAN OF OPERATION

     On February 26, 1998, Intercell Corporation transferred all of the
intellectual property (which had a historical carrying value of zero) of its
wholly owned subsidiary Particle interconnect Corporation to Nanopierce
Technologies, Inc. for stock. Intercell Corporation owns approximately 18% of
the outstanding common stock of Nanopierce Technologies, Inc. as of December 31,
2000.

     During November, 2000, the Company agreed to settle certain litigation and
$135,000 of BMI liabilities by paying $5,000 in cash and exchanging 37,000
restricted common shares of Nanopierce common stock held by the Company (with a
carrying value of $0, a market value of $2.00 per share, and a aggregate market
value of $74,000).  Exchange of the shares resulted in a gain on exchange of
affiliate stock of $74,000 as well as a .07% decrease in the Company's ownership
interest in Nanopierce.  The Company recognized a $56,000 gain on the
settlement, which is presented as a gain on disposal of subsidiary.  The
settlement agreement further stipulates that should the value of the Nanopierce
shares be less than $100,000, based on the closing asked share price, one year
from the date of the settlement, the Company is to exchange additional shares
of Nanopierce in an amount sufficient to obtain the $100,000 value.

     The Company proposes to restructure itself in order to enhance its
prospects for financing, future business operation and acquisitions of new
technologies.  The Company plans to merge into its proposed wholly owned
subsidiary Intercell International Corporation, to change its corporate domicile
to Nevada, effect a 1 for 20 reverse stock split and increase its authorized
capital to permit the issuance of stock to honor certain obligations to deliver
stock assumable upon outstanding convertible and exercisable securities.














                                       13

<PAGE>




RESULTS OF OPERATIONS

Revenues

     The Company had no revenue from continuing operations for the three months
ended December 31, 2000 or 1999.

General and Administrative Expenses

     General and Administrative Expenses were $42,000 in the three months ended
December 31, 2000 compared to $85,000 for 1999.  The decrease is primarily
attributable to a $44,000 decrease in consulting fees.

     During the three months ended December 31, 2000 the Company wrote down the
carrying amount of the Arizcan property from $300,000 to $247,000 based upon a
letter agreement to purchase the property which expires in March 2001.  Based on
the agreement, the Company took impairment on the value of the land of $53,000.

Other Income/Expense

     The Company recognized a gain of $74,000 in the three months ended December
31, 2000 on the exchange of 37,000 shares of Nanopierce common stock.

     Additionally as described below, the consolidated financial statements
reflect Nanopierce Technologies, Inc. (Nanopierce) as an investment accounted
for under the equity method of accounting through September 2000.  The Company's
investment in Nanopierce is carried at zero in the Company's financial
statements and therefore the equity method has been suspended and the Company's
share of Nanopierce's losses has not been recorded.  During the three months
ended December 31, 2000 the Company's voting ownership interest decreased below
20% (approximately 18% at December 31, 2000).

     The Company earned $1,000 in interest income in fiscal year 2000 compared
to $1,000 in fiscal year 1999.  The Company incurred interest expense of $3,000
in the three months ended December 31, 2000 compared to $22,000 in the three
months ended December 31, 1999.  The decrease can be attributed to the
redemption of the outstanding convertible debt in March 2000.

Discontinued Operations

     During November, 2000, the Company agreed to settle certain litigation and
$135,000 of BMI liabilities by paying $5,000 in cash and issuing 37,000
restricted common shares of Nanopierce common stock held by the Company (with a
carrying value of $0, and a aggregate market value of $74,000).  As a result,
the Company recognized a $56,000 gain, which is presented as a gain on disposal
of subsidiary.














                                       14

<PAGE>




Liquidity and Capital Resources

     During the three months ended December 31, 2000 the Company's cash and cash
equivalents used in operating activities of continuing operations was $26,000
primarily resulting from general and administrative expenses.

     During the three months ended December 31, 2000 the Company had no capital
expenditures and no cash flows from financing or other investing activities.

     The Company proposes to restructure itself in order to enhance its
prospects for financing, future business operation and acquisitions of new
technologies.

     To the extent the Company's operations are not sufficient to fund the
Company's capital requirements, the Company may enter into a revolving loan
agreement with a financial institution, attempt to raise additional capital
through the sale of additional capital stock or through the issuance of debt, or
sell shares of Nanopierce common stock held as an investment by the Company.  At
the present time the Company does not have a revolving loan agreement with any
financial institution nor can the Company provide any assurances that it will be
able to enter into any such agreement in the future or be able to raise funds
through the further issuance of debt or equity in the Company.


RECENTLY ISSUED ACCOUNTING STANDARDS

     In June 1998, the FASB issued SFAS NO. 133, Accounting for Derivative
Instruments and Hedging Activities.  This statement, as amended, is effective
for fiscal years beginning after June 15, 2000.  Currently, the Company does not
have any derivative financial instruments and does not participate in hedging
activities; therefore, management believes that SFAS No. 133 will not impact the
Company's financial statements.

     In December 1999, the staff of the Securities and Exchange Commission
issued Staff Accounting Bulletin ("SAB") No. 101, Revenue Recognition in
Financial Statements.  SAB No. 101, as amended by SAB No. 101A and SAB No. 101B,
is effective no later than the fourth fiscal quarter of fiscal years beginning
after December 15, 1999.  SAB No. 101 provides the staff's views in applying
generally accepted accounting principles to selected revenue recognition issues.
Currently, the Company believes that it complies with the accounting and
disclosure described in SAB No. 101; therefore, management believes that SAB No.
101 will not impact the Company's financial statements.


















                                       15

<PAGE>




                           PART II - OTHER INFORMATION


                           ITEM 1.  LEGAL PROCEEDINGS


The Company is involved in various claims and legal actions arising in the
ordinary course of business.  In the opinion of management, the ultimate
disposition of these matters will not have a material adverse effect on the
financial statements of the Company.


                        ITEM 2.     CHANGES IN SECURITIES

The Company made the following unregistered sales of its securities from October
1, 2000 to December 31, 2000.

None


                  ITEM 6.     EXHIBITS AND REPORTS ON FORM 8-K


EXHIBITS

Exhibit 11  Statement of Computation of Net Loss per Share


REPORTS ON FORM 8-K

None





























                                       16

<PAGE>




                                   SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned, thereunto duly authorized.

                                    INTERCELL CORPORATION
                                    (REGISTRANT)

Date:  February 14, 2001               By: /s/  Paul H. Metzinger
                                       --------------------------
                                        Paul H. Metzinger, President,
                                        Chief Executive Officer &
                                        Chief Financial Officer











































                                       17

<PAGE>